Schauer NJ, Liu X, Magin RS, et al. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020;10(1):5324. doi:10.1038/s41598-020-62076-x
Adeegbe DO, Liu S, Hattersley MM, et al. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res. 2018;6(10):1234-1245. doi:10.1158/2326-6066.CIR-18-0077
Sadler JBA, Wenzel DM, Strohacker LK, et al. A cancer-associated polymorphism in ESCRT-III disrupts the abscission checkpoint and promotes genome instability. Proc Natl Acad Sci U S A. 2018;115(38):E8900-E8908. doi:10.1073/pnas.1805504115
Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381-1387. doi:10.1038/s41588-018-0204-y
Chan EM, Shibue T, McFarland JM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551-556. doi:10.1038/s41586-019-1102-x
Najm FJ, Strand C, Donovan KF, et al. Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens. Nat Biotechnol. 2018;36(2):179-189. doi:10.1038/nbt.4048
Stachler MD, Camarda ND, Deitrick C, et al. Detection of Mutations in Barrett’s Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology. 2018;155(1):156-167. doi:10.1053/j.gastro.2018.03.047
Nghiem P, Park PK, Ys Y son K, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem. 2002;277(6):4428-34. doi:10.1074/jbc.M106113200
Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-337.e10. doi:10.1016/j.cell.2018.03.035
O’Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol. 2010;17(10):1218-25. doi:10.1038/nsmb.1897